EMJ GOLD

Nvidia-backed Iambic seeks up to $159.4m in a US IPO as it develops experimental cancer treatments using AI.

The UK’s MHRA welcomes the ASA’s first bans on oral weight-loss medicine adverts and warns advertisers over rule breaches.

The ABPI group will allow teenagers to have a say in how the pharmaceutical industry recruits, communicates and builds trust with Gen Z.

Nobel Prize for Medicine goes to three scientists for their work on optogenetics, a process that has reshaped how scientists study the brain.

Foghorn is cutting around 40% of its workforce after disappointing trial results ended its cancer drug partnership with Lilly.

Experimental drug trevogrumab halved muscle loss when combined with semaglutide in an obesity trial.

Rebounding UK pharma investment, a $3.95m rare-disease gene therapy and Novartis’ CAR-T trial halt. Read the round up now.

Zokovea is the first oral antiviral approved in the EU to prevent symptomatic COVID-19 after exposure.